Mantle Cell Lymphoma (MCL) Withdrawn Phase 3 Trials for Rituximab (DB00073)

Also known as: Mantle Cell Lymphomas / Lymphoma, Mantle-Cell / Mantle-Cell Lymphoma / Lymphoma, Mantle Cell / Mantle Cell Lymphoma / B cell lymphoma / Centrocytic lymphoma / Mantle cell lymphoma NOS

IndicationStatusPhase
DBCOND0071979 (Mantle Cell Lymphoma (MCL))Withdrawn3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02735876A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaTreatment